+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Schizophrenia Drugs Market 2019-2025

  • PDF Icon


  • May 2020
  • Region: Global
  • Orion Market Research Private Limited
  • ID: 5129830
UP TO OFF until Dec 31st 2022
Global Schizophrenia Drugs Market Size, Share & Trends Analysis Report by Therapeutic Class (Second-Generation Antipsychotics, Third-Generation Antipsychotics, and Others) and by treatment (Oral and Injectables) and Forecast 2019-2025.

The global schizophrenia drugs market is projected to witness considerable growth during the forecast period. The major factors contributing to the growth of the market include the increasing focus of healthcare organizations towards the betterment of mental disorders, supported by growing insurance claims. In addition, increasing stress level is further leading to the growing burden mental disorders, including schizophrenia, which in turn, is propelling the schizophrenia drugs market across the globe. The schizophrenia drugs market is classified on the basis of therapeutic class and treatment. Based on therapeutic class, the market is segmented into second-generation antipsychotics, third-generation antipsychotics, and other therapeutic class. Among these therapeutic class, the second-generation antipsychotics are majorly used in therapeutic classes for the treatment of schizophrenia. Based on treatment, the market is bifurcated into oral and injectables.

Geographically, the global schizophrenia drugs market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. North America is expected to contribute a significant share in the global market. The region has a significant population with mental health disorders, such as anxiety and schizophrenia, which in turn, is driving the growth of the schizophrenia drugs market in the region. Along with this, the presence of key market players, such as Eli Lilly and Co. and Johnson & Johnson Services, Inc., is another major factor for the growth of the market in North America. In addition, Asia-Pacific is expected to propel at a considerable growth rate during the forecast period. This growth can be accredited to the growing awareness towards mental health disorders in China, India and other emerging economies.

The global schizophrenia drugs market is influenced by product development and advancements conducted by the market players. The key players of the schizophrenia drugs market include Allergan PLC, Catalent, Inc., Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Co., AstraZeneca PLC, and Johnson & Johnson Services, Inc. These players are playing a significant role in the growth of the schizophrenia drugs market by providing various products and adopting several strategies such as merger and acquisition, partnerships and collaboration, technological development, and others.

Research Methodology

The market study of the global schizophrenia drugs market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook.

In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of the reports.

Secondary sources include:
  • Financial reports of companies involved in the market
  • White papers, research-papers, and news blogs
  • Company websites and their product catalog

The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation:

1. Global Schizophrenia Drugs Market Research and Analysis by Therapeutic Class
2. Global Schizophrenia Drugs Market Research and Analysis by Treatment

The Report covers:
  • Comprehensive research methodology of the global schizophrenia drugs market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global schizophrenia drugs market.
  • Insights about market determinants which are stimulating the global market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Allergan PLC Overview Financial Analysis SWOT Analysis Recent Developments
3.3.2. Otsuka Pharmaceutical Co., Ltd. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.3. Johnson & Johnson Services, Inc. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.4. Eli Lilly and Co. Overview Financial Analysis SWOT Analysis Recent Developments
3.3.5. AstraZeneca PLC Overview Financial Analysis SWOT Analysis Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Schizophrenia Drugs Market by Therapeutic Class
5.1.1. Second Generation Antipsychotics
5.1.2. Third Generation Antipsychotics
5.1.3. Others (First Generation Antipsychotics)
5.2. Global Schizophrenia Drugs Market by Treatment
5.2.1. Oral
5.2.2. Injectables
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. AiCure, LLC
7.2. Alkermes PLC
7.3. Allergan PLC
7.4. AstraZeneca PLC
7.5. Biogen Inc.
7.6. Catalent, Inc.
7.7. Eli Lilly and Co.
7.8. H. Lundbeck A/S
7.9. Indivior PLC
7.10. Johnson & Johnson Services, Inc.
7.11. Lupin Ltd.
7.12. Merck & Co., Inc.
7.13. Minerva Neurosciences, Inc.
7.14. Otsuka Pharmaceutical Co., Ltd.
7.15. Pfizer Inc.
7.16. Sunovion Pharmaceuticals Inc.
7.17. Teva Pharmaceutical Industries Ltd.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • AiCure, LLC
  • Alkermes PLC
  • Allergan PLC
  • AstraZeneca PLC
  • Biogen Inc.
  • Catalent, Inc.
  • Eli Lilly and Co.
  • H. Lundbeck A/S
  • Indivior PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Minerva Neurosciences, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.